Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Disc Medicine ( (IRON) ) has shared an announcement.
Disc Medicine reported that on February 13, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter for its New Drug Application for bitopertin as a treatment for erythropoietic protoporphyria, halting its bid for accelerated approval. The FDA agreed Phase 2 AURORA and BEACON data showed bitopertin significantly lowers the PPIX biomarker, but found no sufficient evidence that reductions in PPIX translated into improved sunlight-exposure outcomes in those trials.
Regulators indicated they want to see results from the ongoing Phase 3 APOLLO study before considering traditional approval, effectively pushing any U.S. decision on bitopertin into at least mid-2027. Disc, which completed APOLLO enrollment earlier than expected and held about $791 million in cash and securities at year-end 2025, plans a Type A meeting with the FDA and maintains it has funding runway into 2029, tempering near-term regulatory disappointment with longer-term development and liquidity visibility.
The most recent analyst rating on (IRON) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on Disc Medicine stock, see the IRON Stock Forecast page.
Spark’s Take on IRON Stock
According to Spark, TipRanks’ AI Analyst, IRON is a Neutral.
The score is held back primarily by pre-revenue financials with rising losses and accelerating cash burn, alongside weak technical momentum. Offsetting factors include a comparatively strong, low-leverage balance sheet and positive, recent corporate developments around bitopertin and pipeline progress that support the longer-term thesis.
To see Spark’s full report on IRON stock, click here.
More about Disc Medicine
Disc Medicine, Inc., based in Watertown, Mass., is a biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. Its pipeline targets fundamental pathways of red blood cell biology, including heme biosynthesis and iron homeostasis, with programs such as bitopertin for erythropoietic porphyrias.
Average Trading Volume: 580,224
Technical Sentiment Signal: Buy
Current Market Cap: $2.72B
For detailed information about IRON stock, go to TipRanks’ Stock Analysis page.